A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Inclusion Criteria: Prior to Surgery: * Body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive * Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic block) not to include base wedge procedure After Surgery: * Subject reported pain of ≥4 on the NPRS, and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) within 9 hours after removal of the popliteal sciatic block on Day 1 * Subject is lucid and able to follow commands * All analgesic guidelines were followed during and after the bunionectomy Exclusion Criteria: Prior to Surgery: * History in the past 10 years of malignancy, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ * History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) * History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN) * History of peripheral neuropathy * A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses * Prior medical history of bunionectomy or other foot surgery * Intolerant of or unwilling to receive hydrocodone, acetaminophen, or ibuprofen * For female subjects: Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose * For male subjects: Male subjects with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose After Surgery: * Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair; or experienced medical complications during the bunionectomy that, in the opinion of the investigator, should preclude randomization Other protocol defined inclusion/exclusion criteria may apply.